Omalizumab biosimilar (Yuanda Shuyang)

奥马珠单抗生物类似药（远大蜀阳）

Report date: 2024/12/31 15:14:20

Base Information

Drug NameOmalizumab biosimilar (Yuanda Shuyang)
Drug Alias NameSYB-507
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionImmunoglobulin E inhibitorsImmunosuppressants
TargetsImmunoglobulin E
Therapy Area/IndicationsAllergic asthmaChronic UrticariaAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesYuanda Shuyang Life Sciences (Chengdu) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYuanda Shuyang Life Sciences (Chengdu) Co Ltd
Inactive CompaniesN/A
Active IndicationsAllergic asthmaChronic UrticariaAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A